Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
ABSI · Why this verdict
Why Absci (ABSI) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.6/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Absci's quality metrics sit well below the engine's investable floor, with heavy cash burn, a negative risk/reward setup, and no clear technical edge, even as a supportive analyst mention and light insider buying provide the only offsetting signals.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The quality score of 1.4 sits far below the 4.0 floor required for a position, driven by a Piotroski F-score of 2 out of 9 and free cash flow running deeply negative relative to revenue. Quality breakdown | The Piotroski F-score should climb out of the bottom quartile and free cash flow as a share of revenue should narrow toward breakeven over the next 12 months if quality is stabilizing. | ↓Deteriorating |
| CounterA current ratio of 6.4 shows the balance sheet holds substantial near-term liquidity, giving the company runway to absorb continued cash burn without an immediate funding crisis. | ||
The position has already reached its resistance-based target with only 1.6% upside against 7.0% downside, producing a negative risk/reward ratio of -0.18 that failed the engine's asymmetry gate. Targets | A fresh resistance level would need to open at least 10% of upside room relative to the 7.0% stop distance for the risk/reward to turn favorable again over the next 12 months. | →Stable |
| CounterMomentum remains strong at 6.8, with price still accumulating volume above the 200-day moving average, which could carry price through resistance and reset a higher target. | ||
The engine classifies this setup as having no clear edge and caps position size recommendation at avoid, citing the binary nature of the biotechnology industry as a suitability concern. Edge rationale | A defined chart setup and a suitability rationale beyond 'speculative' should emerge over the next 12 months for position sizing to move off the avoid recommendation. | ↓Deteriorating |
| CounterAll momentum-related gates passed, including the 6.8 momentum score clearing the 5.5 threshold and a clean 8-K filing check, suggesting the setup is not deteriorating on every dimension. | ||
Short interest of 27% and a put/call ratio of 3.44 signal the options and short-selling market is positioned bearishly, with the risk notes describing the short interest as justified. Risk breakdown | Short interest should decline toward single digits and the put/call ratio should fall back toward parity over the next 12 months if bearish positioning is unwinding. | ↑Improving |
| CounterElevated short interest combined with high implied volatility of 132% raises the possibility of a short-covering rally if any positive catalyst emerges. | ||
Over the last four quarters the company has missed twice, posted one in-line result, and beaten once, leaving the average surprise at -10.1% ahead of the next report in 41 days. Earnings | The average earnings surprise should turn positive and beats should outnumber misses over the next four quarters if execution is improving. | ↑Improving |
| CounterThe most recent quarter was a beat of 4.59%, the best result of the trailing four, which could mark an inflection after the prior miss. | ||
The quality score of 1.4 sits far below the 4.0 floor required for a position, driven by a Piotroski F-score of 2 out of 9 and free cash flow running deeply negative relative to revenue.
↓DeterioratingQuality breakdown
- Expectation
- The Piotroski F-score should climb out of the bottom quartile and free cash flow as a share of revenue should narrow toward breakeven over the next 12 months if quality is stabilizing.
CounterA current ratio of 6.4 shows the balance sheet holds substantial near-term liquidity, giving the company runway to absorb continued cash burn without an immediate funding crisis.
The position has already reached its resistance-based target with only 1.6% upside against 7.0% downside, producing a negative risk/reward ratio of -0.18 that failed the engine's asymmetry gate.
→StableTargets
- Expectation
- A fresh resistance level would need to open at least 10% of upside room relative to the 7.0% stop distance for the risk/reward to turn favorable again over the next 12 months.
CounterMomentum remains strong at 6.8, with price still accumulating volume above the 200-day moving average, which could carry price through resistance and reset a higher target.
The engine classifies this setup as having no clear edge and caps position size recommendation at avoid, citing the binary nature of the biotechnology industry as a suitability concern.
↓DeterioratingEdge rationale
- Expectation
- A defined chart setup and a suitability rationale beyond 'speculative' should emerge over the next 12 months for position sizing to move off the avoid recommendation.
CounterAll momentum-related gates passed, including the 6.8 momentum score clearing the 5.5 threshold and a clean 8-K filing check, suggesting the setup is not deteriorating on every dimension.
Short interest of 27% and a put/call ratio of 3.44 signal the options and short-selling market is positioned bearishly, with the risk notes describing the short interest as justified.
↑ImprovingRisk breakdown
- Expectation
- Short interest should decline toward single digits and the put/call ratio should fall back toward parity over the next 12 months if bearish positioning is unwinding.
CounterElevated short interest combined with high implied volatility of 132% raises the possibility of a short-covering rally if any positive catalyst emerges.
Over the last four quarters the company has missed twice, posted one in-line result, and beaten once, leaving the average surprise at -10.1% ahead of the next report in 41 days.
↑ImprovingEarnings
- Expectation
- The average earnings surprise should turn positive and beats should outnumber misses over the next four quarters if execution is improving.
CounterThe most recent quarter was a beat of 4.59%, the best result of the trailing four, which could mark an inflection after the prior miss.
Per-dimension breakdown
Quality
1.5/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.0 |
| Piotroski F | 3.3 |
- ▸Cash-burning: FCF -3241% of revenue
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 3/9
- ▸Quality concerns
Growth
0.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 0.0 |
- ▸Declining revenue: -46%
Momentum
7.1/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 9.8 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 2.3 |
- ▸Overbought (RSI 71)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.1/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 3.8 |
| Analyst rating | 8.0 |
| Price target | 9.6 |
- ▸Light analyst coverage (9.0) — signal dampened
- ▸Analyst upside: 51%
Insider
6.7/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.5 |
| holder change | 7.5 |
| notable moves | 7.0 |
- ▸Insider buying (low materiality) — $148,866 (0.009% of mkt cap)
- ▸Institutions accumulating
Peer rank
4.0/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 1.9 |
| growth rank | 2.1 |
Technical
3.0/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.1 |
| support resistance | 1.6 |
| 52w position | 5.2 |
Risk (lower is worse)
3.3/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 0.8 |
| days to cover | 0.6 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| beta | 1.9 |
| debt equity | 9.9 |
- ▸High short interest justified: 27%
- ▸High IV: 121%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
4.3/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
| news activity | 8.0 |
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (8)
- MOMENTUM:7.1>=5.5
- ASYMMETRY:2.1>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:92d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (0)
none
Reward-to-Risk
2.11
Upside
+31.6%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($1.6B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects clean gate clearance against Value at 9.0 and asymmetric R:R of 2.11.
The strongest dimensions are Value at 9.0, Momentum at 7.1, and Sentiment at 7.1; the weakest are Growth at 0.0, Quality at 1.5, and Technical at 3.0. The V9 engine cleared all gates, producing an asymmetric reward-to-risk of 2.11 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Quality Below Investable Floor
Trip ifQuality score rises above 4.0 from the current 1.4.
- P2Negative Asymmetry At Target
Trip ifUpside to a revised target exceeds 10% while downside to stop stays under 7.0%.
- P3No Edge Speculative Sizing Cap
Trip ifPosition size recommendation moves beyond avoid as asymmetry ratio rises above 0.
- P4Elevated Short Interest And Put Call
Trip ifShort interest falls below 10% of float from the current 27%.
- P5Mixed Earnings Track Record
Trip ifAverage earnings surprise rises above 0% over the next 2 reported quarters.